European Union - English - myHealthbox

genzyme therapeutics ltd - alemtuzumab - concentrate for solution for infusion - 12 mg alemtuzumab in 1.2 ml (10 mg/ml) - multiple sclerosis - selective immunosuppressants - indicated for adult patients with relapsing remitting multiple sclerosis (rrms) with active disease defined by clinical or imaging features

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genzyme therapeutics ltd - alemtuzumab - solution for infusion - 10mg/1ml

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - alemtuzumab - infusion, solution concentrate - alemtuzumab 12 mg/1.2 ml

European Union - English - EMA (European Medicines Agency)

sanofi belgium - alemtuzumab - multiple sclerosis - selective immunosuppressants - lemtrada is indicated for adult patients with relapsing-remitting multiple sclerosis (rrms) with active disease defined by clinical or imaging features.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

schering health care ltd - alemtuzumab - solution for infusion - 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genzyme therapeutics ltd - alemtuzumab - solution for infusion - 30mg/1ml

Canada - English - Health Canada

genzyme corporation - alemtuzumab - solution - 10mg - alemtuzumab 10mg - antineoplastic agents

Canada - English - Health Canada

sanofi genzyme, a division of sanofi-aventis canada inc - alemtuzumab - solution - 30mg - alemtuzumab 30mg - antineoplastic agents

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

sanofi-aventis south africa (pty) ltd - infusion (parenteral) - see ingredients - each vial contains alemtuzumab 12,0 mg